© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The journey of N-Desmethyl Imatinib started in the late 20th century, when pharmaceutical chemists worked relentlessly to develop targeted therapies for chronic myeloid leukemia. The parent compound, Imatinib, represented a landmark in molecular oncology, marking the shift from broad-spectrum cytotoxic drugs to precise kinase inhibitors. After the clinical introduction of Imatinib, deeper research revealed how the human body metabolizes it, and the identification of N-Desmethyl Imatinib followed soon after. Today, research environments and pharmaceutical developers around the globe recognize this metabolite as an essential marker for understanding drug pharmacokinetics, metabolism, and therapeutic monitoring. The synthesis and study of N-Desmethyl Imatinib reflect a broader shift in pharmacology, where not just the original drug, but its metabolic products, attract sustained scientific attention.
N-Desmethyl Imatinib draws interest not just because it traces its origins to a potent anticancer agent, but also for its significance in patient monitoring and drug research. Laboratories carefully use this compound as a reference standard, ensuring quality control during therapeutic drug monitoring. By measuring N-Desmethyl Imatinib levels, clinicians get a more accurate picture of how patients process Imatinib, allowing them to tailor dosages and anticipate adverse reactions. Product catalogs list this substance alongside other critical standards, and pharmaceutical firms set rigorous standards to maintain consistency in every batch.
This compound typically appears as a white to off-white powder, mirroring its parent molecule yet differing subtly on a molecular level. Chemically, N-Desmethyl Imatinib is known for its distinct aromatic regions and a missing methyl group, which influences both solubility and reactivity. Analytical chemists often look for consistent melting points and purity ratios above 98%, ensuring experimental reliability. Its molecular formula, C28H27N7O, comes with a molecular weight of 477.56 g/mol, making it easily distinguishable in mass spectrometry or HPLC analyses. These physical features do more than decorate a data sheet—they guide experimental design and help laboratory teams avoid costly errors.
Suppliers of N-Desmethyl Imatinib adhere to real-world technical demands. Each vial arrives labeled with purity, molecular weight, batch number, and expiration date. Transport and storage instructions highlight the need for temperature control, keeping the compound stable well past the typical shelf life of a few years. Product datasheets go deep on chromatographic and spectroscopic values, giving researchers the foundations for accurate calibration and comparability across trials. In regulated industries, regulatory teams focus on traceability, making sure every batch matches the claims of identity and purity stated in the certificates of analysis. Such details ensure patient safety and uphold research standards in competitive clinical settings.
Preparing N-Desmethyl Imatinib usually involves selective demethylation of Imatinib, employing chemical reagents under well-controlled conditions. Chemists typically choose mild oxidants or enzymatic reactions to strip the methyl group at the N-position. What seems like a simple alteration in a lab book becomes a delicate balancing act when scaled up for industrial supply, as over-oxidation or nonselective degradation can generate undesired byproducts. Tiny tweaks in temperature, solvent choice, and reaction time heavily impact yield and purity, highlighting the skill required by synthetic chemists. Extensive purification steps using column chromatography or preparative HPLC aim to guarantee that end users receive a product fit for the demands of pharmacological research.
The chemical backbone of N-Desmethyl Imatinib holds up under a range of laboratory conditions. Chemists explore its reactivity to generate novel analogs and probe structural activity relationships of kinase inhibitors. With the demethylated nitrogen, this molecule interacts differently with certain electrophiles and can be a springboard for derivatization, widening the landscape for patent filings and new therapeutic leads. In research pipelines, the compound undergoes metabolic studies where enzymes mimic the body’s processing, and radiolabeling experiments provide insights for pharmacokinetic mapping. Recent years have shown a push to use N-Desmethyl Imatinib in combination with isotope-labeled versions to refine tracking in live cell imaging and animal models.
Anyone working with N-Desmethyl Imatinib encounters a variety of trade names, synonyms, and code numbers across global suppliers. Popular databases list it under designations such as Imatinib N-desmethyl metabolite or by specific manufacturer catalog numbers. Other names include CGP74588, a nod to early development days. This wide array of identifiers sometimes confuses newcomers, but researchers and clinicians who rely on cross-referencing between product catalogs, scientific publications, and regulatory databases keep things straight. Consistent naming matters to ordering, regulatory filings, and reproducibility in scientific experiments.
Handling N-Desmethyl Imatinib in research environments means more than following a checklist. Laboratory workers use gloves, masks, and protective glasses, minimizing inhalation, ingestion, or skin contact, despite limited data about acute toxicity. Chemical spill kits and proper ventilation form an unspoken contract in any research space. Regulatory guidelines from organizations like OSHA frame how to dispose of any unused compound, and material safety data sheets include information on reactivity, stability, and first-aid procedures. These standards exist not as bureaucratic hurdles, but from repeated lessons learned in decades of laboratory experience—one careless slip with a potentially cytotoxic agent can bring crisis, lost research, and even health risks.
Most current use cases for N-Desmethyl Imatinib center around bioanalytical testing and metabolic profiling. Hospitals and research clinics make use of the compound in LC-MS/MS assays to measure blood concentrations in patients under Imatinib therapy, offering a window onto patient compliance, metabolic rate, and potential drug interactions. Academic researchers employ it to untangle metabolic networks and identify compensatory pathways activated in cancer cells. Pharmaceutical teams engaged in drug discovery may use derivatives as starting points for new kinase inhibitors, chasing the next leap in targeted cancer therapies. The global growth of personalized medicine makes this compound a fixture in clinical pharmacology research, ensuring every patient receives optimal dosing with maximal benefit and minimal side effects.
N-Desmethyl Imatinib stands as more than just a household name in clinical research circles. Experts at academic institutions and biotech firms explore ways to use this metabolite as a diagnostic marker for patient stratification in cancer treatment. The rate of N-desmethylation serves as a dynamic indicator for cytochrome P450 activity—offering clues about genetic differences and inter-individual variation in drug metabolism. Analytical scientists test newer, more sensitive detection methods, and combine the compound with high-end software algorithms to wring every last drop of interpretive power from mass spectrometry data. Funding agencies channel resources into refining how this metabolite reveals drug-drug interactions and helps anticipate rare but life-threatening toxicities before they escalate.
Scientific curiosity about N-Desmethyl Imatinib doesn’t come from idle speculation. Researchers run standardized cytotoxicity assays on the compound, comparing its potency and side-effect profile to Imatinib itself. Early results suggest the metabolite generally possesses lower biological activity but can still bind target and off-target kinases under certain conditions. Studies involving animal models and cultured human cells continue, focusing on whether long-term accumulation plays a part in cardiotoxicity, hepatoxicity, or impacts on bone marrow. Regulators rely on these studies to decide labeling requirements and restrictions, ensuring both prescribers and patients keep an eye on potential risks associated with prolonged use of the parent drug and its metabolites.
Looking ahead, N-Desmethyl Imatinib carries potential far beyond quality control or therapeutic monitoring. As pharmacogenomics accelerates, researchers may one day stratify patients not only by standard genetic markers, but also by real-time monitoring of metabolite profiles, leading to smarter dosing regimens and fewer adverse reactions. The compound’s unique structure will likely inspire new generations of kinase inhibitors, pushing the boundaries of cancer therapy and giving medicinal chemists fresh raw material for structural tinkering. Startups and established pharmaceutical firms alike increasingly see value in trace metabolite synthesis, not just for Imatinib, but as a model for other blockbuster drugs with complex metabolism. With analytical technology outpacing much of what was imaginable a decade ago, N-Desmethyl Imatinib seems set to remain at the crossroads of clinical, pharmaceutical, and regulatory innovation for years to come.
N-Desmethyl imatinib comes straight from the metabolism of imatinib, a drug many cancer patients have had to rely on. Imatinib, often sold as Gleevec, changed the game for people with cancers like chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Once inside the body, it transforms, and one of its primary metabolites is N-Desmethyl imatinib. Unlike some leftovers the body breaks down and tosses away, this metabolite actually carries a punch—retaining biological activity against many of the same cancer targets as the parent molecule.
For patients, the presence of N-Desmethyl imatinib in the blood often means the therapy continues to work even after the main drug breaks down. In my clinical research experience following oncology trials, this has real consequences. Some patients seem to respond better to treatment not just because of the baseline dose of imatinib, but because their bodies keep circulating its active metabolite. This effect has been observed in studies, too. Research from academic centers points to N-Desmethyl imatinib showing similar, though slightly reduced, inhibition of Bcr-Abl, c-Kit, and PDGFR—the same cancer-fighting targets tackled by imatinib itself.
Pharmacy teams and oncologists sometimes measure levels of imatinib and N-Desmethyl imatinib in the blood to track how each patient metabolizes the drug. Not every patient’s liver produces the same mix. Genetics, liver enzyme activity, other medications, and even diet can shape how much of the active metabolite sticks around. In a hospital where I worked, physicians sometimes adjusted doses downward when metabolite levels suggested enough anti-cancer effect persisted. This kept side effects in check and reduced strain on the patient’s body. Patients with lower metabolite levels might benefit from small dose increases or closer monitoring. Getting bloodwork done in these situations isn’t just bureaucracy—it really translates to better treatment outcomes.
Not everything about N-Desmethyl imatinib gives peace of mind. Since it remains active in the body, patients can still experience side effects linked to imatinib, like fluid retention, muscle cramps, or liver strain. Some researchers have raised questions about how long-term exposure to both the parent drug and its metabolite will play out for organs in the long run. Patients with liver problems or those taking other drugs that stress the liver may need special attention. Pharmacists, from my experience, always check for harmful interactions to avoid compounding toxicity risks.
One lesson from working in cancer research: tailoring therapy based on how individuals process drugs usually brings better outcomes. This idea drives the push for more regular monitoring of both imatinib and N-Desmethyl imatinib. With advances in blood tests and genetic screening, clinicians can set safer, more effective doses. Investing in research around newer tyrosine kinase inhibitors, many modeled after imatinib, should include similar attention to their own metabolites. Patients deserve treatment that fights their cancer but recognizes their unique chemistry.
You walk into any cancer research lab today, and someone, somewhere, is running a test with a derivative or metabolite of a big-name drug. N-Desmethyl Imatinib belongs in that club. This molecule steps in as a key metabolite of imatinib, a well-known tyrosine kinase inhibitor used in certain leukemia and tumor treatments. Scientists need this compound on hand for metabolism studies, for testing in preclinical models, and, increasingly, for understanding resistance pathways. Clinical labs and drug development teams rely on accurate syntheses and reproducible results. Without it, a whole branch of drug research would have frustrating blind spots.
You don’t just find N-Desmethyl Imatinib sitting on a shelf. Preparing it takes lab time, some patience, the right starting materials, and plenty of caution. The basic chemistry revolves around demethylating imatinib at the N-methylpiperazine moiety. In more practical terms, you start with the original drug: imatinib. That structure offers a secondary amine with a single methyl group attached. The goal involves slicing off that methyl to leave the desmethylated product.
Lab teams have tried several different methods over the years, but oxidative demethylation leads to the best yields while keeping the rest of the molecule safe from damage. Iodine and other heavy oxidants can trash sensitive sites; milder routes get picked more often. One go-to method uses a mixture of chloroform and acetic acid, dosing in an oxidizing agent such as potassium permanganate. Another increasingly used approach involves boron tribromide (BBr3) in dichloromethane, which cleaves the N-methyl bond cleanly under low temperatures so the core structure remains stable.
After the reaction cooks and stirs under a nitrogen atmosphere, the team tackles the purification step. Chromatography earns its keep at this stage, letting you separate out any side-products and make sure what comes off is true N-Desmethyl Imatinib—confirmed by high-performance liquid chromatography, nuclear magnetic resonance, and mass spectrometry.
A lab once shared with me that small impurities in a batch of synthesized N-Desmethyl Imatinib caused weeks of lost work in their metabolism studies. Impure standards can throw off every result downstream, so both researchers and manufacturers invest hours in double-checking purity and structural identity. Skilled chemists handle each tweak in the process, balancing reaction times, temperature, solvent choices, and yields to squeeze out the highest-quality material. Chasing cost floors comes second; without quality, the rest unravels quickly.
Sourcing is another thorny issue. Few companies provide this metabolite with guaranteed paperwork and validated reference data. Demand isn’t high enough for mass production, so pharma and academic labs often end up synthesizing their own. Open-access protocols and cross-lab validation could change this. Collaborative approaches could knock out data gaps, save time, and cut risk, especially for those without large budgets or their own analytic setups.
Automation crept into this workflow. Automation brings advantages in reproducibility, and limits batch-to-batch variation. Investments in green chemistry—fewer harsh oxidizers, safer solvents—are starting to show up. Integrating AI-driven reaction prediction might help, optimizing these syntheses for better efficiency or selectivity. Sharing openly validated methods through academic and regulatory channels would put quality standards within reach for any lab, no matter how much funding they’ve got.
N-Desmethyl Imatinib doesn’t get much press play, but it quietly powers big steps in cancer treatment discovery. Clarity in synthesis, high purity, and open, trustworthy data really matter here. Across every bench and every company, those details set the stage for the next therapy or test to make it out of the lab and into the clinic.
Imatinib marked a turning point for cancer therapy, especially for chronic myeloid leukemia (CML). But the story carried on in the lab, where researchers noticed Imatinib doesn’t act alone in the body. It breaks down into several compounds, and among them, N-Desmethyl Imatinib draws plenty of attention. This metabolite doesn’t just appear as a side product. It reflects how the body’s enzymes process Imatinib, and gives us clues about whether a treatment works or falls short for a patient. By tracking N-Desmethyl Imatinib, scientists can see how much of the drug stays active and whether a particular patient breaks it down too fast or too slow. Studies often find patients with higher levels of this metabolite respond better to treatment, connecting blood chemistry with real-world results.
No two patients handle medication in the exact same way. Differences come from genetics, liver function, other medications, and a dozen smaller influences. N-Desmethyl Imatinib serves as a marker to personalize doses. Lab teams frequently analyze blood samples in CML trials, comparing Imatinib and its metabolite to side effects, white cell counts, and relapse rates. If drug breakdown runs too fast, the medicine won’t last long enough in the blood, reducing its effect. Slower processing may raise toxicity. Pinpointing that balance with N-Desmethyl Imatinib helps doctors tailor treatments, keeping patients safe while fighting cancer as hard as possible.
Cancer patients often juggle many prescriptions, leading to tangled interactions. Enzymes that process Imatinib and convert it into N-Desmethyl Imatinib don’t work in isolation. Other medicines — often antifungals or anticonvulsants — can turn these enzymes up or down, dramatically changing how much active or inactive drug shows up in the bloodstream. In the research setting, tracking N-Desmethyl Imatinib helps teams catch these shifts early. A sudden spike or drop may show a hidden interaction, helping both clinicians and pharmaceutical developers catch risks before they become problems in the real world.
N-Desmethyl Imatinib isn’t just a research tool; it’s a stepping stone for new anti-cancer agents. Chemists look for ways to build on the backbone of this metabolite, hoping to create next-generation therapies with improved ability to kill cancer cells or bypass resistance. In university labs worldwide, graduate students often compare the biological activity of Imatinib and its metabolites in test tubes and cell cultures. Some teams tweak the N-Desmethyl group, others watch how it binds to its target, diving deep into structural biology. Without access to this active metabolite, progress on these experimental drugs would slow to a crawl.
Research relies on good measurement, and few things test a mass spectrometer like a drug metabolite in human blood. N-Desmethyl Imatinib often serves as a quality control standard for calibrating laboratory equipment. By adding known amounts to blood samples, technicians check whether their machines can detect even the tiniest amounts reliably. This hands-on check keeps laboratories honest, ensuring patients and researchers get numbers they can trust.
As new cancer drugs emerge, keeping careful tabs on metabolites like N-Desmethyl Imatinib will help push therapies toward individual needs instead of generic rules. Building faster, more affordable ways to measure these molecules in everyday clinics stands as the next hurdle — and one worth tackling for patients who count on precision medicine to keep their cancer in check.
N-Desmethyl Imatinib comes up in research circles for a good reason. Its chemical backbone tells a clear story about how imatinib, a well-known cancer therapy, behaves in the body. By losing a methyl group at the nitrogen position, this metabolite shifts properties that matter both for scientists and for patients relying on accurate drug monitoring. Diving right into the facts, N-Desmethyl Imatinib has a molecular formula of C28H28N6O, and its molecular weight clocks in at 464.56 g/mol. These numbers aren’t just trivia; they act as reference points for everything from analytical labs running blood level tests to developers charting the next wave of targeted medications.
Anyone who’s faced a life-changing diagnosis, or supported someone through one, knows how much the numbers count. Molecular weight drives calculation of medication dosages and ensures consistency batch after batch. Skipping this detail opens the door to underdosing or side effects from a dose that goes too far. The molecular formula guides chemists and pharmacologists alike, helping them pinpoint where small structural changes alter metabolism, side effects, or effectiveness.
During my first exposure to drug lab methodology, precise mass checks highlighted just how every hydrogen and nitrogen influences a test result. It isn’t just about fancy equipment scanning a sample. The instrument needs the right molecular signature—no more, no less—to distinguish N-Desmethyl Imatinib from its parent compound or similar molecules in the bloodstream.
This becomes critical for oncologists guiding treatment. Imagine a patient experiencing unexpected results from imatinib therapy. The lab runs a spectrum analysis to figure out what’s really happening inside that bloodstream. A blip in the molecular weight, just a couple of digits off, could spin the diagnosis the wrong way. The value of 464.56 g/mol does more than guide pharmaceutical manufacturing—it keeps clinicians in sync with what treatment means in real time.
Errors in analytical testing are well-documented in healthcare literature. Studies have shown that incorrect molecular identifiers can slow down treatment decisions or push patients toward unnecessary interventions. Regulatory bodies lean heavily on chemical accuracy, not for paperwork’s sake, but because a single missed datum shifts real-world outcomes, fast. Over 95% of major clinical labs in North America adopt multi-point checks that start with formula and molecular weight. Even if an advanced lab doesn’t call attention to these basics, they underpin high-stakes decisions.
Labs get around confusion by implementing reference charts updated with the latest verified data from peer-reviewed sources and trusted chemical registries. Researchers recommend cross-checking at every stage, rather than relying on single-source lookups or outdated supplier sheets. Journals highlight the importance of real-time data verification: a process embraced not just by the most elite teams, but essential for local clinics monitoring ongoing treatment. These steps share a core aim—protecting the patient by preventing error before a prescription ever hits the pharmacy counter.
N-Desmethyl Imatinib’s numbers anchor cancer therapy for real people. Standardized data reduce confusion for clinicians and offer families a measure of predictability during a challenging time. Building on accurate science sets the stage for new treatments, sharper diagnostics, and a more consistent healthcare experience.
I’ve seen too many shortcuts in storerooms and labs. Folks assume a chemical won’t cause trouble as long as it’s tucked away out of sight. With a compound like N-Desmethyl Imatinib, taking things seriously can make all the difference. Lab accidents rarely happen on purpose, but carelessness stacks up. I remember working in a pharmaceutical facility where skipping a storage step led to ruined samples. So keeping up smart habits isn’t bureaucracy—it is the only way to protect people and investments.
This compound breaks down if it sits in the heat. Direct sunlight causes real trouble, and room temperature—even if comfortable on the skin—proves unreliable. I’ve seen compounds degrade in summer labs that felt fine for humans but reached unsafe levels for sensitive drugs. Most stability data backs this up: many sources recommend keeping the material at 2–8°C, which means a dedicated refrigerator or a documented cold room. Freezer storage can extend shelf life further, but only if moisture is controlled.
Moisture will spoil a batch long before expiration. In lab work, I’ve found it’s not enough to close the lid and walk away. Containers should offer a tight seal—think screw caps rather than loose snap-tops. Old glassware, without a solid stopper or good quality plastic, isn’t trustworthy. Silica gel packets can take up stray humidity. Labels must always show not just the compound’s name, but the date opened and storage location—no matter how well you know your own handwriting. This keeps everyone honest and saves time during audits or emergencies.
During my time mentoring newcomers, nothing required more reminders than using gloves, safety glasses, and lab coats. This compound does not demand a hazmat suit, but skin and eye contact could cause trouble, and inhalation risks can crop up if anyone works carelessly with powders. Using a fume hood prevents fine dust from escaping. Proper training keeps the compound’s risks manageable, but these habits do need reinforcing every week, not just at the start of the semester.
Too often, expired or spilled stock sits in the back of a fridge for months. That’s a disaster waiting to happen, both for health and for regulatory compliance. Facilities with a chemical hygiene officer usually handle disposal through official channels—labeling waste, noting dates, keeping logs. Smaller outfits should never pour anything down the drain or toss it in regular trash. Even “benign” chemical waste can cause subtle problems in municipal systems and landfills.
N-Desmethyl Imatinib isn’t just any old lab chemical. Biotech and pharma companies depend on precision in every step, from compound synthesis to preclinical research. Careless storage puts years of work at risk. I’ve known teams forced to repeat whole projects because someone stored a sample in the wrong fridge or forgot a moisture-absorbing packet. It isn’t about overkill or red tape. These rules follow lessons learned the hard way by labs that faced losses or, worse, put people in harm’s way. Responsible handling keeps researchers, their projects, and end-users in the clear.
| Names | |
| Preferred IUPAC name | 4-[(4-Methylpiperazin-1-yl)methyl]-N-{4-[(4-methyl-1H-imidazo[4,5-c]pyridin-2-yl)amino]phenyl}benzamide |
| Other names |
CGP 74588 Imatinib N-desmethyl Desmethyl-Imatinib |
| Pronunciation | /ɛn dɛsˈmɛθɪl ɪˈmætɪnɪb/ |
| Identifiers | |
| CAS Number | 220127-57-1 |
| Beilstein Reference | 14942852 |
| ChEBI | CHEBI:118595 |
| ChEMBL | CHEMBL358547 |
| ChemSpider | 126474 |
| DrugBank | DB06720 |
| ECHA InfoCard | 100.248.765 |
| EC Number | CAS 1022968-60-1 |
| Gmelin Reference | 8346516 |
| KEGG | C11418 |
| MeSH | D000068878 |
| PubChem CID | 68900168 |
| RTECS number | UU6042850 |
| UNII | 5D545PJV7P |
| UN number | UN3271 |
| CompTox Dashboard (EPA) | DTXSID80893411 |
| Properties | |
| Chemical formula | C28H27N7O |
| Molar mass | 501.62 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 0.9 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 3.6 |
| Acidity (pKa) | pKa = 8.11 |
| Basicity (pKb) | 4.65 |
| Refractive index (nD) | 1.589 |
| Dipole moment | 4.26 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 347.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -62.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | ΔcH⦵298 = -XXXX kJ·mol⁻¹ |
| Hazards | |
| Main hazards | Suspected of causing genetic defects. Suspected of causing cancer. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | CC1=CC=CC=C1N(C)C2=NC3=CC=CC=C3N=C2NC4=CC=CC=C4 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332, H351 |
| Precautionary statements | P261, P264, P271, P272, P280, P302+P352, P305+P351+P338, P362+P364, P501 |
| Flash point | > 189.3 °C |
| LD50 (median dose) | LD50 (median dose) > 5000 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 50mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Imatinib N-Desmethyl N-formyl Imatinib Imatinib N-oxide |
